PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 18194152-8 2008 Pindolol produced a dose-dependent decrease in the buspirone prolactin response. Pindolol 0-8 prolactin Homo sapiens 61-70 11713611-7 2001 RESULTS: Pindolol alone caused a small but significant reduction (18%) in the tonic release of prolactin. Pindolol 9-17 prolactin Homo sapiens 95-104 15093954-4 2004 Since the release of cortisol and prolactin is under serotonergic control, we hypothesized that pindolol augmentation of synaptic 5-HT concentrations produced by an SSRI in humans should lead to enhanced SSRI-induced cortisol and prolactin responses. Pindolol 96-104 prolactin Homo sapiens 34-43 15093954-4 2004 Since the release of cortisol and prolactin is under serotonergic control, we hypothesized that pindolol augmentation of synaptic 5-HT concentrations produced by an SSRI in humans should lead to enhanced SSRI-induced cortisol and prolactin responses. Pindolol 96-104 prolactin Homo sapiens 230-239 14533141-0 2003 Effect of pindolol and milnacipran versus milnacipran and placebo on plasma prolactin and adrenocorticotrophic hormone in depressed subjects. Pindolol 10-18 prolactin Homo sapiens 76-85 14533141-2 2003 The present study analyses the relationship between plasma prolactin (PRL) and ACTH levels and changes in relation to a milnacipran and pindolol combination versus milnacipran plus placebo. Pindolol 136-144 prolactin Homo sapiens 59-68 14533141-2 2003 The present study analyses the relationship between plasma prolactin (PRL) and ACTH levels and changes in relation to a milnacipran and pindolol combination versus milnacipran plus placebo. Pindolol 136-144 prolactin Homo sapiens 70-73 15013031-7 2004 RESULTS: Pindolol significantly antagonized ACTH, PRL, GH and temperature responses to flesinoxan and ritanserin exhibited similar activity on PRL and ACTH responses. Pindolol 9-17 prolactin Homo sapiens 50-53 11713611-8 2001 Buspirone alone produced a robust prolactin response which was reduced to approximately half by pindolol pre-treatment. Pindolol 96-104 prolactin Homo sapiens 34-43 11713611-9 2001 Pindolol pre-treatment also, on average, delayed the onset and peak of the prolactin response. Pindolol 0-8 prolactin Homo sapiens 75-84 11713611-12 2001 However, if two challenges are carried out, one with buspirone and the other with buspirone plus pindolol, quantitative measures can be made of the sensitivity of both the 5-HT(1A) and the putative D(2) pathways controlling prolactin release. Pindolol 97-105 prolactin Homo sapiens 224-233 9026379-5 1996 Pindolol significantly increased basal plasma cortisol concentrations, whereas it decreased plasma prolactin (PRL) concentrations and body temperature. Pindolol 0-8 prolactin Homo sapiens 99-108 9524980-5 1998 The results indicated that +/- pindolol decreases PRL concentrations depending on personality. Pindolol 31-39 prolactin Homo sapiens 50-53 9026379-5 1996 Pindolol significantly increased basal plasma cortisol concentrations, whereas it decreased plasma prolactin (PRL) concentrations and body temperature. Pindolol 0-8 prolactin Homo sapiens 110-113 7495925-0 1995 Effect of pindolol pretreatment on MK-212-induced plasma cortisol and prolactin responses in normal men. Pindolol 10-18 prolactin Homo sapiens 70-79 7495925-4 1995 The MK-212-induced response in plasma cortisol was not diminished by pindolol pretreatment, whereas the MK-212-induced PRL response was significantly inhibited by pindolol pretreatment. Pindolol 163-171 prolactin Homo sapiens 119-122 7675967-2 1995 Pindolol pretreatment attenuated the (+)-fenfluramine-induced increase in prolactin concentrations but failed to affect the (+)-fenfluramine-induced cortisol increase. Pindolol 0-8 prolactin Homo sapiens 74-83 7568634-0 1995 Effect of pindolol on the prolactin response to d-fenfluramine. Pindolol 10-18 prolactin Homo sapiens 26-35 7568634-1 1995 We studied the effect of the 5-HT1A receptor antagonist, pindolol, on the prolactin (PRL) response to the 5-HT releasing agent, d-fenfluramine (d-FEN), in ten healthy male volunteers. Pindolol 57-65 prolactin Homo sapiens 74-83 7568634-1 1995 We studied the effect of the 5-HT1A receptor antagonist, pindolol, on the prolactin (PRL) response to the 5-HT releasing agent, d-fenfluramine (d-FEN), in ten healthy male volunteers. Pindolol 57-65 prolactin Homo sapiens 85-88 7568634-2 1995 Pindolol pretreatment lowered baseline PRL levels but, when this effect was taken into account, did not significantly attenuate the PRL response to d-FEN. Pindolol 0-8 prolactin Homo sapiens 39-42 8471832-0 1993 Prolactin and thyrotropin responses to ECT after pindolol administration. Pindolol 49-57 prolactin Homo sapiens 0-9 7855226-0 1994 Effect of pindolol on the L-5-HTP-induced increase in plasma prolactin and cortisol concentrations in man. Pindolol 10-18 prolactin Homo sapiens 61-70 7855226-4 1994 Pretreatment with pindolol, 30 mg orally, significantly inhibited the PRL but not the cortisol response to L-5-HTP, 200 mg PO. Pindolol 18-26 prolactin Homo sapiens 70-73 7855226-5 1994 Pindolol alone decreased basal plasma PRL levels and increased basal plasma cortisol levels, possibly due to 5-HT1A antagonist and agonists effects, respectively. Pindolol 0-8 prolactin Homo sapiens 38-41 8471832-2 1993 The effect of pindolol, a beta-receptor blocker with potent 5-HT1 receptor antagonistic properties, on the prolactin (PRL) and thyrotropin (TSH) responses to electroconvulsive therapy (ECT) was systematically studied in 12 female depressed patients. Pindolol 14-22 prolactin Homo sapiens 107-116 2006240-0 1991 Pindolol decreases prolactin and growth hormone responses to intravenous L-tryptophan. Pindolol 0-8 prolactin Homo sapiens 19-28 2006240-2 1991 Pindolol pretreatment (40 mg over 48 h) markedly attenuated the GH response to LTP and modestly, but significantly, reduced the LTP-induced increase in plasma PRL. Pindolol 0-8 prolactin Homo sapiens 159-162 2274641-4 1990 Pretreatment with the nonselective beta-adrenergic/5-HT1-like antagonist, pindolol suppressed the maximal PRL response to buspirone challenge depending upon dose (i.e., between 49 to 90% suppression at best dose). Pindolol 74-82 prolactin Homo sapiens 106-109